(101 days)
No
The device description and intended use focus on the chemical composition and physical application of a topical skin adhesive. There is no mention of AI, ML, image processing, or any computational analysis of data.
No
The device is intended to hold closed easily approximated skin edges, which is a supportive function, not a direct therapeutic treatment of a disease or condition in the body.
No
The device description clearly states "SURGISEAL Topical Skin Adhesive is a sterile, professional liquid skin adhesive" and its intended use is to "hold closed easily approximated skin edges of wounds from surgical incisions". This indicates it is a therapeutic device used for wound closure, not a diagnostic device used for identifying a disease or condition.
No
The device description clearly states it is a liquid skin adhesive containing chemical components and is applied with a physical applicator, indicating it is a physical medical device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "topical applications only to hold closed easily approximated skin edges of wounds from surgical incisions...". This describes a device used directly on the body for a physical purpose (holding skin edges together).
- Device Description: The description details a "sterile, professional liquid skin adhesive" that polymerizes on the skin. This is a physical adhesive, not a reagent or instrument used to examine specimens in vitro (outside the body).
- Lack of IVD Characteristics: There is no mention of analyzing biological specimens (blood, urine, tissue, etc.), detecting markers, or providing diagnostic information based on in vitro testing.
IVD devices are used to examine specimens taken from the human body to provide information for diagnosis, monitoring, or screening. This device's function is purely mechanical/physical on the body's surface.
N/A
Intended Use / Indications for Use
SURGISEAL Topical Skin Adhesive is intended for topical applications only to hold closed easily approximated skin edges of wounds from surgical incisions, including punctures from minimally invasive surgery, simple, thoroughly cleansed, trauma induced lacerations. SURGISEAL may be used in conjunction with, but not in place of, deep dermal sutures.
Product codes
MPN
Device Description
SURGISEAL® Topical Skin Adhesive is a sterile, professional liquid skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D&C Violet #2. The SURGISEAL Twist applicator contains the identical adhesive formula as the predicate devices, SURGISEAL® Topical Skin Adhesive and SURGISEAL StylusTM Topical Skin Adhesive, but is comprised of a plastic ampoule container contained within an applicator sleeve with the applicator tip. This Twist applicator tray is contained in an outer Tyvek pouch. When SURGISEAL is applied to the skin with either Applicator, it polymerizes in minutes. In intro studies have shown that SURGISEAL acts as a physical barrier to microbial penetration as long as the adhesive film remains intact. Clinical studies were not conducted to demonstrate microbial barrier properties and a correlation between microbial barrier properties and a reduction in infection have not been established.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Skin
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Professional setting
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Bench tests in this submission include Film Thickness determinations for each of the SURGISEAL Teardrop, Stylus and Twist applicators.
The labeling change clarifies the performance of the device in order to characterize the ease, safety, or effective use of the product. Based on extensive bench performance testing, the modified labeled device, SURGISEAL Twist Topical Skin Adhesive, has demonstrated to be safe & efficacious.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
SURGISEAL® Topical Skin Adhesive (K082993, K123936, K130329, K140517), SURGISEAL StylusTM Topical Skin Adhesive (K130474, K140517), SURGISEAL TwistTM Topical Skin Adhesive (K130474)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4010 Tissue adhesive.
(a)
Tissue adhesive for the topical approximation of skin —(1)Identification. A tissue adhesive for the topical approximation of skin is a device intended for topical closure of surgical incisions, including laparoscopic incisions, and simple traumatic lacerations that have easily approximated skin edges. Tissue adhesives for the topical approximation of skin may be used in conjunction with, but not in place of, deep dermal stitches.(2)
Classification. Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: “Tissue Adhesive for the Topical Approximation of Skin.” See § 878.1(e) of this chapter for the availability of this guidance document.(b)
Tissue adhesive for non-topical use —(1)Identification. A tissue adhesive for non-topical use, including adhesives intended for use in the embolization of brain arteriovenous malformation or for use in ophthalmic surgery, is a device used for adhesion of internal tissues and vessels.(2)
Classification. Class III (premarket approval). As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed. See § 878.3 of this chapter.
0
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 21, 2014
Adhezion Biomedical, LLC Tracy Lofgren Regulatory Consultant One Meridian Boulevard, Suite 1B02 Wyomissing, Pennsylvania 19610
Re: K141215
Trade/Device Name: SURGISEAL Twist™ Topical Skin Adhesive Regulation Number: 21 CFR 878.4010 Regulatory Name: Tissue adhesive Regulatory Class: Class II Product Code: MPN Dated: May 28, 2014 Received: May 29, 2014
Dear Ms. Lofgren:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
David Krause -S
Binita S. Ashar, M.D., M.B.A., F.A.C.S. for
Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
2
Indications for Use
510(k) Number (if known) K141215
Device Name SURGISEAL Twist™ Topical Skin Adhesive
Indications for Use (Describe)
SURGISEAL Topical Skin Adhesive is intended for topical applications only to hold closed easily approximated skin edges of wounds from surgical incisions, including punctures from minimally invasive surgery, simple, thoroughly cleansed, trauma induced lacerations.
SURGISEAL may be used in conjunction with, but not in place of, deep dermal sutures
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image contains the logo for Adhezion Biomedical. The logo consists of a stylized blue symbol on the left, resembling interconnected curves. To the right of the symbol is the word "Adhezion" in a bold, sans-serif font, with the word "BIOMEDICAL" in a smaller font size underneath. The overall design is clean and modern.
Section 7: 510(k) Summary
A summary of 510(k) safety and effectiveness information in accordance with the requirements of 21 CFR 807.92 is below:
| Requirements of 21 CFR 807.92 is below. | |
|---|---|
| Submitter Information: | |
| Name | Adhezion Biomedical, LLC |
| Address | One Meridian Boulevard |
| Suite 1B02 | |
| Wyomissing, PA 19610 | |
| Phone Number | (610) 241-7191 |
| Fax Number | (610) 373-2081 |
| Establishment | |
| Registration | 3006385287 |
| Name of contact | |
| person(s) | Richard Jones, Regulatory and Quality Assurance Consultant |
| Tracy Lofgren, Regulatory Consultant | |
| Date prepared | August 1, 2014 |
| Name of Device: | |
| Trade or proprietary | |
| name | SURGISEAL TwistTM Topical Skin Adhesive |
| Common or usual | |
| name | Device, Tissue Adhesive for Topical Approximation |
| Classification name | Class II |
| Classification Panel | General and Plastic Surgery Devices |
| Regulation | Class II, under 21 CFR 878.4010 |
| Product Code(s) | MPN |
| Legally Marketed | |
| device(s) to which | |
| equivalence is | |
| claimed | SURGISEAL® Topical Skin Adhesive (K082993, K123936, K130329, K140517) |
| SURGISEAL StylusTM Topical Skin Adhesive (K130474, K140517) | |
| SURGISEAL TwistTM Topical Skin Adhesive (K130474) | |
| Reason for 510(k) | |
| submission | Labeling Change to include Microbial Barrier description |
| Device Description | SURGISEAL® Topical Skin Adhesive is a sterile, professional liquid |
| skin adhesive containing a monomeric (2-octyl cyanoacrylate) | |
| formulation and the colorant D&C Violet #2. The SURGISEAL Twist | |
| applicator contains the identical adhesive formula as the predicate | |
| devices, SURGISEAL® Topical Skin Adhesive and SURGISEAL | |
| StylusTM Topical Skin Adhesive, but is comprised of a plastic ampoule | |
| container contained within an applicator sleeve with the applicator tip. | |
| This Twist applicator tray is contained in an outer Tyvek pouch. When | |
| SURGISEAL is applied to the skin with either Applicator, it | |
| polymerizes in minutes. | |
| In vitro studies have shown that SURGISEAL acts as a physical barrier | |
| Indications for use | SURGISEAL is intended for topical applications only to hold closed easily approximated skin edges of wounds from surgical incisions, including punctures from minimally invasive surgery, simple, thoroughly cleansed, trauma induced lacerations. |
| SURGISEAL may be used in conjunction with, but not in place of, deep dermal sutures. to microbial penetration as long as the adhesive film remains intact. Clinical studies were not conducted to demonstrate microbial barrier properties and a correlation between microbial barrier properties and a reduction in infection have not been established. | |
| Technological | |
| Characteristics | The technological characteristics of each applicator design are geometrically unique but have similar capabilities for adhesive deployment and film coverage. The predicate Teardrop applicator shape is flat with a small specific depth incorporating a smooth, wide foam surface tip for larger area coverage; whereas, the subject Twist applicator shape is tubular with a smaller width angled tip for a more precision deployment with less peripheral coverage. Each has a unique distinctive design for releasing the identical SurgiSeal formula to the tip for patient skin contact. |
| SURGISEAL adhesive consists of a monomeric (2-octyl cyanoacrylate) liquid adhesive formulation packaged in a single-use applicator. The device is a low viscosity formulation to allow for varied layered applications of the adhesive to the intended area and allow for either a single consistent intact film thickness, continuous layer or two thin layers of the adhesive to the wound area. | |
| SURGISEAL is used for topical applications only to hold closed, easily approximated skin edges of wounds while maintaining wound approximation. | |
| In vitro studies have shown that SURGISEAL acts as a physical barrier to microbial penetration as long as the adhesive film remains intact. Clinical studies were not conducted to demonstrate microbial barrier properties and a correlation between microbial barrier properties and a reduction in infection have not been established. | |
| Substantial | |
| Equivalence | Biocompatibility: |
| Biocompatibility testing was previously conducted on the currently marketed device, SURGISEAL Twist (K130474), per the International Standard ISO-10993, “Biological Evaluation of Medical Devices, Part 1: Evaluation and Testing”. The existing testing is deemed supportive of the proposed labeled devices. Based on the results from those studies, both proposed labeled devices are considered to be non-toxic, | |
| biocompatibility testing was necessary as the subject device is identical | |
| to the device identified in K130474. | |
| Performance Testing: | |
| Bench tests in this submission include Film Thickness determinations | |
| for each of the SURGISEAL Teardrop, Stylus and Twist applicators. | |
| Sterilization and Shelf-Life | |
| SURGISEAL Twist™ Topical Skin Adhesive is sterilized in | |
| accordance with the order of operation of the assembly. The filled | |
| ampoule containing the adhesive is sterilized by gamma irradiation in | |
| accordance with ISO 11137-2:2006. Then the finished bulk applicator | |
| in the secondary packaging is sterilized by ethylene oxide in accordance | |
| with ISO 11135-1:2008 and ISO 11135-2:2008. | |
| The proposed labeling modification sterilization does not impact the 24 | |
| month (2 year) expiration date (shelf-life) proposed for these products | |
| and will therefore remain to be labeled with a two (2) year expiration | |
| date. |
4
5
The labeling change clarifies the performance of the device in order to characterize the ease, safety, or effective use of the product. Based on extensive bench performance testing, the modified labeled device, SURGISEAL Twist Topical Skin Adhesive, has demonstrated to be safe & efficacious.